uniQure N.V. QURE now represents more than a single-program gene therapy story. Its profile is being reshaped by faster regulatory pathways, a narrower operating model and clinical work in rare neurological diseases.
Those trends matter because investors are watching whether uniQure can build the next phase of growth beyond HEMGENIX-related economics and obligations.
uniQure Is Leaning Into Regulatory Speed
AMT-130 remains the main trend marker. The Huntington’s disease gene therapy has received Regenerative Medicine Advanced Therapy, Breakthrough Therapy and Fast Track designations from the FDA, highlighting the unmet need around a disease with no disease-modifying treatment.
Recent FDA feedback revived hopes for a faster path. During a Type B meeting, the agency indicated that three-year phase I/II data could serve as the primary basis for a biologics license application seeking accelerated approval, while still requiring alignment on the confirmatory study design.
That fits a broader biotechnology theme. High-need therapies may gain faster regulatory routes when the data package is compelling enough. PTC Therapeutics PTCT, whose PTC518 program has received Fast Track designation for Huntington’s disease, gives investors another example of regulatory urgency.
uniQure N.V. Price and Consensus
uniQure N.V. price-consensus-chart | uniQure N.V. Quote
QURE Is Becoming a More Focused Business
uniQure is also simplifying its operating model. After selling its commercial manufacturing business to Genezen in 2024, the company moved in 2026 to transfer HEMGENIX manufacturing responsibilities directly to Genezen.
The remaining HEMGENIX supply and minimum purchase commitments are expected to end after delivery of specified batches, with no impact on future royalties or milestone payments. That shift reduces non-core complexity while preserving CSL Behring economics.
The result is a more focused research-and-development company. Sarepta Therapeutics SRPT, which has a rare neuromuscular portfolio including gene therapy and exon-skipping treatments in Duchenne muscular dystrophy, shows why execution remains central for genetic medicine companies.
uniQure Is Expanding in CNS Disorders
AMT-260 shows how uniQure is expanding beyond Huntington’s disease into central nervous system disorders. The candidate is being studied in refractory mesial temporal lobe epilepsy, where many patients remain inadequately controlled despite anti-seizure medications.
Initial six-month data from the first low-dose cohort showed that three of six patients had reductions in disabling seizures during months four through six ranging from 79% to 100% from baseline. The other three patients had mixed results, ranging from a 33% reduction to a 36% increase.
The data suggest early biological activity, but they also show the complexity of central nervous system gene therapy. Larger and longer studies will be needed to clarify safety, dosing and durability.
QURE Still Shows the Risks of Innovation
uniQure’s platform ambition also brings setbacks. AMT-162, once in development for SOD1-associated amyotrophic lateral sclerosis, was discontinued after a review of preliminary safety and efficacy data.
That decision followed a voluntary enrollment pause after a serious adverse event was identified as a dose-limiting toxicity. The discontinuation removed a potential long-term growth asset and increased reliance on AMT-130.
This is the trade-off in emerging gene therapy platforms. Multiple shots on goal can broaden opportunity, but setbacks can quickly raise concentration risk around the lead program.
uniQure’s Runway Supports the Next Phase
Capital discipline gives uniQure time. As of March 31, 2026, the company held $586.6 million in cash, cash equivalents and current investment securities.
Management expects those resources to fund operations into the second half of 2029. That runway supports regulatory work, clinical studies and commercial preparation while the company adapts to a more focused structure.
The cash position does not remove clinical or regulatory risk. It does, however, reduce near-term financing pressure as uniQure pursues key milestones.
How QURE’s Ratings Reflect the Trend Trade
The bottom line is that QURE offers exposure to important gene therapy trends, but the stock still depends on proof that AMT-130 can move from regulatory promise toward approval and commercialization.
The stock currently carries a Zacks Rank #3 (Hold), which fits a wait-and-see setup. The company has catalysts, but AMT-130 still requires confirmatory-study alignment and execution. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Momentum Score of B aligns with renewed investor interest in regulatory upside. Yet the Value Score of F, Growth Score of F and VGM Score of F show that QURE does not screen well across traditional fundamental measures.
Research Chief Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
uniQure N.V. (QURE) : Free Stock Analysis Report
Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report
PTC Therapeutics, Inc. (PTCT) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.